Sun Pharmaceutical Industries Ltd announced that US FDA has granted an approval for the Abbreviated New Drug Application (ANDA) to market generic Paraplatin, carboplatin injection.

These generic versions of carboplatin 10mg/ml injections packed in 5 ml, 15ml and 45 ml single use vials are bio-equivalent to Paraplatin injections distributed by Bristol Myers Squibb Oncology/Virology.

Carboplatin injections are indicated as initial and secondary therapy in patients with advanced ovarian carcinoma.

These strengths of Paraplatin injections have annual sales of approximately USD 45 million in the US.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd is an international, integrated, speciality pharmaceutical company.